Novo Nordisk A/S (NYSE:NVO) Short Interest Update

18 Apr 2026, 17:06 by Renee Jackson · The Cerbat Gem

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was the recipient of a large drop in short interest in March. As of March 31st, there was short interest totaling 19,927,815 shares, a drop of 19.3% from the March 15th total of 24,696,357 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 18,061,163 shares, the days-to-cover ratio is currently 1.1 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, April 7th. Finally, Wolfe Research started coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Four research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $65.56.

Get Our Latest Report on NVO

Novo Nordisk A/S Price Performance

Shares of NVO traded down $0.46 on Friday, hitting $40.47. The company’s stock had a trading volume of 13,172,209 shares, compared to its average volume of 15,718,670. The company has a 50 day moving average price of $40.07 and a 200 day moving average price of $48.46. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company has a market capitalization of $180.72 billion, a PE ratio of 11.66, a PEG ratio of 9.65 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were given a dividend of $1.2751 per share. The ex-dividend date was Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s payout ratio is presently 50.43%.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. True Wealth Design LLC boosted its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $30,000. Finally, WealthCollab LLC increased its stake in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Novo benefits from a modest U.S. launch for Eli Lilly’s new oral obesity pill, which recorded only 1,390 prescriptions in its debut week — a slow start that helps preserve Novo’s lead in the GLP-1/weight-loss market. Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
Positive Sentiment: A new pre-peer-review study suggests Novo’s semaglutide preserves lean body mass better than Lilly’s tirzepatide, supporting a potential clinical differentiation that could influence physician prescribing and payor decisions. Novo weight-loss drug may preserve lean body mass better than Lilly’s, study finds
Positive Sentiment: The FDA requested additional safety data from Lilly on its Foundayo launch, a near-term regulatory hiccup for Lilly that can indirectly help Novo by slowing competitor momentum. Lilly Stock Dips on FDA Request for More Foundayo Safety Data
Positive Sentiment: Company capacity is expanding: reports say Novo Nordisk has added ~2,000 staffers this year, signaling preparation for continued demand and commercialization scale-up. Novo Nordisk has reportedly added 2,000 to workforce this year
Neutral Sentiment: Analyst coverage continues to include Novo among large-cap health names highlighted by Zacks — attention is positive for liquidity but not an immediate catalyst. The Zacks Analyst Blog Highlights Netflix, PepsiCo, Novo Nordisk
Neutral Sentiment: Big biotech financing continues: Kailera’s large IPO shows investor interest and capital flow into obesity drug developers — increases sector activity but not an immediate threat to Novo’s franchise. Kailera nets $625M in one of biotech’s biggest-ever IPOs
Negative Sentiment: Generics pressure: Hetero Labs aims to roll out 1.5M generic semaglutide pens annually as it expands globally — a longer-term pricing and share risk for Novo in certain markets. Indian’s Hetero targets annual sales of 1.5 million semaglutide pens in global rollout
Negative Sentiment: Sector-wide weakness in healthcare equities is creating downward pressure on peer stocks, which can amplify short-term moves in Novo’s share price despite company-specific positives. Sector Update: Health Care Stocks Lower in Afternoon Trading

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.